SXTP vs. EDSA, BFRG, SYBX, RLYB, ALVR, FLGC, IMNN, TXMD, ME, and ASBP
Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Edesa Biotech (EDSA), Bullfrog AI (BFRG), Synlogic (SYBX), Rallybio (RLYB), AlloVir (ALVR), Flora Growth (FLGC), Imunon (IMNN), TherapeuticsMD (TXMD), 23andMe (ME), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry.
60 Degrees Pharmaceuticals vs. Its Competitors
60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.
60 Degrees Pharmaceuticals has a beta of 2.78, indicating that its share price is 178% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
60 Degrees Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 192.28%. Edesa Biotech has a consensus price target of $5.00, suggesting a potential upside of 134.74%. Given 60 Degrees Pharmaceuticals' higher possible upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Edesa Biotech.
8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 22.6% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Edesa Biotech has lower revenue, but higher earnings than 60 Degrees Pharmaceuticals. Edesa Biotech is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -1,947.30%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Edesa Biotech's return on equity.
In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Edesa Biotech. 60 Degrees Pharmaceuticals' average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.
Summary
60 Degrees Pharmaceuticals beats Edesa Biotech on 8 of the 15 factors compared between the two stocks.
Get 60 Degrees Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
60 Degrees Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:SXTP) was last updated on 7/5/2025 by MarketBeat.com Staff
